No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine

OBJECTIVE: To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS: Meta-analysis of phase III trials of licensed DMDs for pwRMS and a phase III trial of cladribine (CLARITY). Cancer rates were compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Pakpoor, Julia, Disanto, Giulio, Altmann, Daniel R., Pavitt, Sue, Turner, Benjamin P., Marta, Monica, Juliusson, Gunnar, Baker, David, Chataway, Jeremy, Schmierer, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592538/
https://www.ncbi.nlm.nih.gov/pubmed/26468472
http://dx.doi.org/10.1212/NXI.0000000000000158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592538/
https://www.ncbi.nlm.nih.gov/pubmed/26468472
http://dx.doi.org/10.1212/NXI.0000000000000158

Ejemplares similares